Shares of ARS Pharmaceuticals (NASDAQ:SPRY) rose 13% Friday after the company announced it had received FDA approval for its epinephrine nasal spray for ... for a sublingual oral formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback